Hansa Biopharma reported positive Phase 3 trial results for imlifidase, an enzyme that cleaves antibodies to enable kidney transplants for highly sensitized patients on dialysis. The trial showed significantly improved kidney function at 12 months among treated patients compared to control, measured by estimated glomerular filtration rate. The company plans to submit a biologics license application (BLA) by year-end. This therapy could address a critical barrier to transplantation and improve outcomes for patients with advanced kidney disease.